PI3K/AKT信号通路与miR-203在食管癌中的研究进展

摘要
图/表
参考文献(38)
相关文章 (15)

全文: PDF (0 KB) HTML (44 KB)
输出: BibTeX | EndNote (RIS)

摘要食管癌是原发食管上皮的恶性肿瘤，发病机制复杂。在食管癌中，磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（AKT）是参与其中并经常被激活的信号通路之一，其异常激活可促进食管癌的发展。miR-203 为小分子非编码RNA，长度为19～22 个核苷酸，在多种恶性组织中表达异常。miR-203 可通过与靶基因的3′UTR 结合，在转录后水平发挥基因调控作用，与肿瘤发展进程密切相关。近年来有文献报道，miR-203 可以通过PI3K/AKT 通路影响相关基因表达，从而影响食管癌细胞的增殖凋亡、侵袭迁移，与食管癌的发展进程、临床治疗、患者预后有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄慧
	殷彩桥
	陈婷

关键词 ：食管癌, PI3K/AKT, 信号通路, miR-203

Abstract：

Esophageal cancer is a malignant tumor originating from the esophageal epithelium with complex pathogenesis. In esophageal cancer, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) is one of the signaling pathways involved and often activated, its abnormal activation can promote the development of esophageal cancer. The miR-203 is a small non-coding RNA molecule generally 19-22 nucleotides in length, with abnormal expression in multiple malignant tissues. The miR-203 regulates gene expression at the post-transcriptional level by binding to the 3′UTR of the target gene, which is closely related to the tumor development process. In recent years, many literatures report that miR-203 can influence the expression of related genes through PI3K/AKT pathway, thus affecting the proliferation,apoptosis, invasion and migration of esophageal cancer cells, which is related to the progression of esophageal cancer,clinical treatment and prognosis of patients.

Key words： Esophageal cancer PI3K/AKT Signaling pathway miR-203

基金资助:湖北省恩施州科技计划面上项目（E20180004）

通讯作者: 殷彩桥（1966-），女，博士，主任医师，硕士研究生导师，研究方向：食管癌

作者简介: 黄慧（1992-），女，湖北民族大学2018 级在读硕士研究生，研究方向：食管癌；陈婷（1991-），女，硕士，研究方向：食管癌

引用本文:

黄慧；殷彩桥；陈婷. PI3K/AKT信号通路与miR-203在食管癌中的研究进展[J]. 中国当代医药, 2021, 28(3): 29-33.
HUANG Hui；YIN Cai-qiao； CHEN Ting. Research progress of PI3K/AKT signaling pathway and miR-203 in esophageal cancer. 中国当代医药, 2021, 28(3): 29-33.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I3/29

[1]	Guanen Q，Junjie S，Baolin W，et al.MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway[J].Biomed Pharmacother，2018，105：350-361.
[2]	Manning BD，Toker A.AKT/PKB Signaling：Navigating the Network[J].Cell，2017，169（3）：381-405.
[3]	Fruman DA，Chiu H，Hopkins BD，et al.The PI3K Pathway in Human Disease[J].Cell，2017，170（4）：605-635.
[4]	Manning BD，Cantley LC.AKT/PKB signaling：navigating downstreamk[J].Cell，2007，129（7）：1261-1274.
[30]	Weichhart T.mTOR as Regulator of Lifespan，Aging，and Cellular Senescence：A Mini-Review[J].Gerontology，2018，64（2）：127-134.
[31]	Yang H，Rudge DG，Koos JD，et al.mTOR kinase structure，mechanism and regulation[J].Nature，2013，497（7448）：217-223.
[5]	JavadiniaSA，ShahidsalesS，Fanipakdel A，et al.The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs：a Novel Marker for Prognosis，and a Possible Target for Immunotherapy[J].Curr Pharm Des，2018，24（39）：4646-4651.
[6]	Tasioudi KE，Sakellariou S，Levidou G，et al.Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma[J].APMIS，2015，123（8）：639-647.
[7]	Li B，Xu WW，Lam AKY，et al.Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy[J].Oncotarget，2017，8（24）：38 755-38 766.
[8]	Zhang LN，Zhao L，Yan XL，et al.Loss of G3BP1 suppresses proliferation，migration，and invasion of esophageal cancer cells via Wnt/β-catenin and PI3K/AKT signaling pathways[J].J Cell Physiol，2019，234（11）：20 469-20 484.
[9]	Sheng J，Deng X，Zhang Q，et al.PAR-2 promotes invasion and migration of esophageal cancer cells by activating MEK/ERK and PI3K/Akt signaling pathway[J].Int J Clin Exp Pathol，2019，12（3）：787-797.
[10]	Wang G，Sun J，Zhao H，et al.Long Non-Coding RNA （lncRNA）Growth Arrest Specific 5（GAS5）Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase （PI3K）/AKT/Mammalian Target of Rapamycin （mTOR） Signaling Pathway[J].Med Sci Monit，2018，24：7689-7696.
[11]	Xia D，Tian S，Chen Z，et al.miR302a inhibits the proliferation of esophageal cancer cells through the MAPK and PI3K/Akt signaling pathways[J].Oncol Lett，2018，15（3）：3937-3943.
[12]	Chen HX，Liu YS，Zhang XJ.TargetScore used to reveal potential targets of miRNA203 and miRNA-146a in psoriasis by integrating microRNA overexpression and microarray data[J].Medicine （Baltimore），2018，97（41）：e12671.
[13]	Xia Y，Wang Y，Wang Q，et al.Increased miR-203-3p and reduced miR-21-5p synergistically inhibit proliferation，migration，and invasion in esophageal cancer cells[J].Anticancer Drugs，2019，30（1）：38-45.
[14]	Yuan Y，Zeng ZY，Liu XH，et al.MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma[J].BMC Cancer，2011，11：57.
[15]	Takeshita N，Mori M，Kano M，et al.miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1[J].Int J Oncol，2012，41（5）：1653-1661.
[18]	殷彩桥，方呈祥，陈婷，等.miR-203a-3p 通过靶向调控GATA6 抑制食管鳞癌细胞的增殖和侵袭[J].中国癌症杂志，2020，30（6）：441-448.
[19]	Wang L，Zhang Z，Yu X，et al.SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression[J].Cancer Lett，2020，468：14-26.
[29]	Shi N，Yu H，Chen T.Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway[J].Onco Targets Ther，2019，12：7637-7647.
[16]	Zhang F，Yang Z，Cao M，et al.MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer[J].Cancer Lett，2014，342（1）：121-129.
[17]	Zong M，Feng W，Wan L，et al.miR-203 affects esophageal cancer cell proliferation，apoptosis and invasion by targeting MAP3K1[J].Oncol Lett，2020，20（1）：751-757.
[20]	Alqahtani A，Ayesh HSK，Halawani H.PIK3CA Gene Mutations in Solid Malignancies：Association with Clinicopathological Parameters and Prognosis[J].Cancers（Basel），2019，12（1）：93.
[21]	Zhang A，Lakshmanan J，Motameni A，et al.MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA，p38 MAPK，c-Jun，and GSK3 signaling[J].Mol Cell Biochem，2018，441（1-2）：89-98.
[22]	Pereira L，Horta S，Mateus R，et al.Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome[J].Drug Discov Today，2015，20（9）：1152-1158.
[23]	Li J，Chen Y，Zhao J，et al.miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression[J].Cancer Lett，2011，304（1）：52-59.
[24]	Wang-Bishop L，Chen Z，Gomaa A，et al.Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1[J].Gastroenterology，2019，156（3）：662-675.e7.
[25]	Hancox U，Cosulich S，Hanson L，et al.Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel[J].Mol Cancer Ther，2015，14（1）：48-58.
[26]	Caino MC，Ghosh JC，Chae YC，et al.PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion[J].Proc Natl Acad Sci U S A，2015，112（28）：8638-8643.
[27]	Molife LR，Yan L，Vitfell-Rasmussen J，et al.Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel，docetaxel，or erlotinib in patients with advanced solid tumors[J].J Hematol Oncol，2014，7：1.
[28]	Ou DL，Lee BS，Lin LI，et al.Vertical blockade of the IGFRPI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma：the role of survivin[J].Mol Cancer，2014，13：2.
[32]	Conciatori F，Ciuffreda L，Bazzichetto C，et al.mTOR Cross-Talk in Cancer and Potential for Combination Therapy[J].Cancers（Basel），2018，10（1）：23.
[33]	Zhang CΗ，Awasthi N，Schwarz MA，et al.The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer[J].Int J Oncol，2013，43（5）：1627-1635.
[34]	Manara MC，Nicoletti G，Zambelli D，et al.NVP-BEZ235 as a new therapeutic option for sarcomas[J].Clin Cancer Res，2010，16（2）：530-540.
[35]	Liu H，Zhao J，Fu R，et al.The ginsenoside Rk3 exerts anti-esophageal cancer activity in vitro and in vivo by mediating apoptosis and autophagy through regulation of the PI3K/Akt/mTOR pathway[J].PLoS One，2019，14（5）：e0216 759.
[36]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[37]	Tang JC，An R，Jiang YQ，et al.Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo[J].Cancer Res Treat，2017，49（3）：778-789.
[38]	Jin Y，Xu K，Chen Q，et al.Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway[J].Exp Cell Res，2018，362（2）：362-369.